Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 65 results
Filters: First Letter Of Title is E  [Clear All Filters]
Found 65 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

B

Bakshi RP, Hamzeh F, Frank I, et al. "Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients." AIDS Res. Hum. Retroviruses. 2007;23(11):1360-5.
Bar KJ, Sneller MC, Harrison LJ, et al. "Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption." N. Engl. J. Med.. 2016;375(21):2037-2050.
Basham RJ, Richardson DM, Sutcliffe CB, Haas DW. "Effect of HIV-1 infection on human DNA yield from saliva." HIV Clin Trials. 2009;10(4):282-5.
Bedimo R, Kang M, Tebas P, et al. "Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients." AIDS Res. Hum. Retroviruses. 2016;32(4):325-8.
Bednasz CJ, Venuto CS, Ma Q, et al. "Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants." Ther Drug Monit. 2017;39(6):596-603.
Bhasin S, Parker RA, Sattler F, et al. "Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity." J. Clin. Endocrinol. Metab.. 2007;92(3):1049-57.
Blackard JT, Kang M, Sherman KE, Koziel MJames, Peters MG, Chung RT. "Effects of HCV treatment on cytokine expression during HCV/HIV coinfection." J. Interferon Cytokine Res.. 2006;26(11):834-8.
Blanchard-Horan C, Stocker V, Moran L, et al. "Examining the challenges and solutions to the implementation of trials in resource-limited settings: Limited Resource Trials." Appl Clin Trials. 2012;21(1):34-42.

G

Gallien S, Delaugerre C, Charreau I, et al. "Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia." AIDS. 2011;25(5):665-9.
Gandhi RT, Spritzler J, Chan E, et al. "Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384." J. Acquir. Immune Defic. Syndr.. 2006;42(4):426-34.
Gandhi RT, Zheng L, Bosch RJ, et al. "The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial." PLoS Med.. 2010;7(8).
Geng EH, Kahn JS, Chang OC, et al. "The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation." Clin. Infect. Dis.. 2011;53(10):1008-14.
Grant PM, Tierney C, Budhathoki C, et al. "Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202." HIV Clin Trials. 2013;14(6):284-91.
Grant PM, Komarow L, Lederman MM, et al. "Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164." J. Infect. Dis.. 2012;206(11):1715-23.
Gupta SK, Smurzynski M, Franceschini N, Bosch RJ, Szczech LA, Kalayjian RC. "The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era." Antivir. Ther. (Lond.). 2009;14(4):543-9.

Pages